9805633-6
IDS COPY

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C12N 15/24, A61K 38/20, C12N 5/08 — A1

(11) International Publication Number: WO 97/42324

(43) International Publication Date: 13 November 1997 (13.11.97)

(21) International Application Number: PCT/US97/07120

(22) International Filing Date: 2 May 1997 (02.05.97)

(30) Priority Data:
08/643,810 6 May 1996 (06.05.96) US

(71) Applicant: SCHERING CORPORATION [US/US]; 2000 Galloping Hill Road, Kenilworth, NJ 07033 (US).

(72) Inventors: RONCAROLO, Maria-Grazia; University of Torino, Dept. of Pediatrics, Immunology Dept., Regina Margherita Children's Hospital, Piazza Polonia, 94, I-10126 Torino (IT). DE WAAL MALEFYT, Rene; 891 Muender Avenue, Sunnyvale, CA 94040 (US). BACCHETTA, Rosa; Res. Trefili, 851, I-20090 Milano Due-Segrate (IT). GROUX, Herve, M.; 3898 Magnolia Drive, Palo Alto, CA 94306 (US). DE VRIES, Jan, E.; Novartis Research Institute, Brunner Strasse 59, A-1235 Vienna (AT).

(74) Agents: FOULKE, Cynthia, L. et al.; Schering-Plough Corporation, Patent Dept. K-6-1 1990, 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US).

(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: USE OF INTERLEUKIN-10 TO PRODUCE A POPULATION OF SUPPRESSOR CELLS

(57) Abstract

Interleukin-10 for producing a population of cells which are capable of inhibiting or suppressing reactions to alloantigens, for example in graft-versus-host disease or tissue rejection, is described. Interleukin-10 for reducing responses in mixed lymphocyte response (MLR) is also described. Exogenous or induced endogenous IL-10 may be used for the inhibition or suppression of the reactions to alloantigens.